Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast canc...
Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
About this item
Full title
Author / Creator
Publisher
London: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central
Subjects
More information
Scope and Contents
Contents
Background Predictive biomarkers are needed to identify oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER + /HER2-) metastatic breast cancer (MBC) patients who would likely benefit from cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine therapy. Therefore, we performed an exploratory study to evaluat...
Alternative Titles
Full title
Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_fc2dab0d63f148118386bce1c3dd78e9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fc2dab0d63f148118386bce1c3dd78e9
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-022-01555-7
